Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
Managing Your Patients
We know it's becoming increasingly difficult to manage all of your patients who have an implanted cardiac device. That's why remote follow-up is so important, and why it's become the standard of care for patients with cardiac devices.1
Today the CareLink™ network is the leading remote monitoring system, with 99.9% of Medtronic devices compatible with the network.2 The network is customizable and flexible, allowing you to move important data to the forefront and view critical transmissions first via CareAlert™ notifications.
The CareLink network gives you — as an implanter — an opportunity to collaborate with heart failure physicians on the care and well-being of heart failure patients who have a cardiac device. This collaboration provides heart failure physicians access to critical diagnostics to manage worsening heart failure.3-8
Access to diagnostic device reports and CareAlert notifications is available 24/7 on the secure CareLink website and the CareLink mobile app — providing you with the information you need to take any necessary action for your patients.*†
Customizable, color-coded CareAlert notifications are available for patients who have wireless devices. The alerts can be designated as Red, Yellow, or Website-only. And the urgency levels can be set clinic-wide or customized for individual patients — when you determine it’s necessary.
Options for being notified of wireless alerts include: website, voice message, pager, text message, or email message.
When a patient's device detects an alert that you have programmed "On," such as AT/AF or a device integrity issue, the device will attempt to make a wireless connection to the patient's monitor immediately for notification — and will re-attempt to communicate as needed. Medtronic wants to ensure that you receive the alert as quickly as possible. With CareAlert notifications, you can focus on your patients and take the action that's needed to provide the best possible care.
As a clinician, we know you're constantly on the go. That's why you're able to get direct access to the same reports available on the CareLink network using your smartphone or tablet and the CareLink mobile app.
Data availability and alert notifications are subject to internet connectivity/access and service availability. The CareLink mobile app is for iOS devices only.
The CareLink and MyCareLink™ monitors must be on and in range of the device. Alert notifications are not intended to be used as the sole basis for making decisions about patient medical care.
Ricci RP, Vicentini A, D’Onofrio A, et al. Impact of in-clinic follow-up visits in patients with implantable cardioverter defibrillators: demographic and socioeconomic analysis of the TARIFF study population. J Interv Card Electrophysiol. November 2013;38(2):101-106.
Devices Supported on the CareLink Network. January 2014. Data on file.
Yu CM, Wang L, Chau E, et al. Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation. August 9, 2005;112(6):841-848.
Whellan DJ, Al-Khatib SM, Kloosterman EM, et al. Changes in Intrathoracic Fluid Index predict subsequent adverse events: Results of the Multisite Program to Access and Review Trending INformation and Evaluate CoRrelation to Symptoms in Patients with Heart Failure (PARTNERS HF) Trial. J Card Fail. November 2008;14(9):799.
Abraham WT, Compton S, Haas G, et al. Superior performance of intrathoracic impedance-derived fluid index versus daily weight monitoring in heart failure patients: results of the Fluid Accumulation Status Trial. Late Breaking Clinical Trials. J Card Fail. November 2009;15(9):813.
Vollmann D, Nägele H, Schauerte P, et al. Clinical utility of intrathoracic impedance monitoring to alert patients with an implanted device of deteriorating chronic heart failure. Eur Heart J. August 2007;28(15):1835-1840.
Catanzariti D, Lunati M, Landolina M, et al, for the Italian Clinical Service OptiVol-CRT group. Monitoring intrathoracic impedance with an implantable defibrillator reduces hospitalizations in patients with heart failure. Pacing Clin Electrophysiol. March 2009;32(3):363-370.
Perego GB, Landolina M, Vergara G, et al. Implantable CRT device diagnostics identify patients with increased risk for heart failure hospitalization. J Interv Card Electrophysiol. December 2008;23(3):235-242.
Apple and the Apple logo are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc.